Pasar al contenido principal

MATERIALES BASADOS EN QUITOSANOS HEPARA(I)NIZADOS: MODIFICACIONES SELECTIVAS PARA NUEVAS APLICACIONES BIOMEDICAS

PID2019-105337RB-C21

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Synthetic heparan sulfate mimics based on chitosan derivatives show broad-spectrum antiviral activity

  • Geller, Ron
  • Revuelta, Julia
  • Rusu, Luciana
  • Francés-Gómez, Clara
  • Trapero, Elena
  • Iglesias, Susana
  • Calvo Pinilla, Eva
  • Blázquez, Ana-Belén
  • Gutiérrez-Adán, Alfonso
  • Konuparamban, Acsah
  • Moreno, Oscar
  • Gómez-Martínez, María
  • Forcada-Nadal, Alicia
  • López-Redondo, Marisa
  • Llácer, José Luis
  • Llop, Jordi
  • Martín-Acebes, M. A.
  • Fernández-Mayoralas, Alfonso
Enveloped viruses enter cells by binding to receptors present on host cell membranes, which trigger internalization and membrane fusion. For many viruses, this either directly or indirectly involves interaction with membrane-anchored carbohydrates, such as heparan sulfate, providing a potential target for a broad-spectrum antiviral approach. Based on this hypothesis, we screened a library of functionalized chitosan sulfates that mimic heparan sulfate in cellular membranes for inhibition of SARS-CoV-2 and respiratory syncytial virus (RSV) entry. An array of compounds blocking SARS-CoV-2 and RSV were identified, with the lead compound displaying broad-spectrum activity against multiple viral strains and clinical isolates. Mechanism of action studies showed the drug to block viral entry irreversibly, likely via a virucidal mechanism. Importantly, the drug was non-toxic in vivo and showed potent post-exposure therapeutic activity against both SARS-CoV-2 and RSV. Together, these results highlight the potential of functionalized carbohydrates as broad-spectrum antivirals targeting respiratory viruses., Funding for this project was provided by grants SGL2021-03-009, SGL2103053, and SGL2021-03-052 from European Union NextGenerationEU/PRTR through the CSIC Global Health Platform established by EU Council Regulation 2020/2094, to RG, to MAM-A, J. R., A. F.-M., J.L.L, and the IBV-Covid19-Pipeline acknowledge the financial support provided by CSIC (grants CSIC-COV19-013, CSIC-COV19-082) and the MICIN (grants PID2019-105337RB-C21, PID2020-120322RB-C21, PID2020-116880GB-I00). RG also acknowledges funding from the Generalitat Valenciana (GVA, GVCOVID19-2020-05). MAM-A acknowledges funding from the European Union’s Horizon Europe research and innovation programme under grant agreement number 101137506 (NAVIPP)., No